Merck & Company, Inc. (MRK) Earnings

Merck & Company, Inc.

MRK · NYSE

Sep 2026upcoming

Next quarter

Consensus is $2.34 EPS for Sep 2026 across 4 estimates, ranging $2.24 to $2.42.

MRK Jun 2026

Reported Aug 4, 2026

Beat 50.00%

EPS estimate: -$0.26
EPS actual: -$0.13
Revenue estimate: —
Revenue actual: —
1-day move: —

Call highlights have not been generated for this quarter.

Symbol: MRK
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Key Issues

Bullish view

Strong oncology performance and newer products helped Merck beat second-quarter estimates, while the company raised and narrowed its 2026 sales outlook.

Bearish view

The evidence also flags Gardasil challenges and Keytruda-related concerns, so current oncology strength may not fully offset weakness elsewhere in the portfolio.

Analyst Consensus

See all

Buy

24 analysts

$129

Current

—

Low

$137

Average

—

High

Average target implies +6.23% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Novartis AGNVS · NYSE$154.50